Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Sarcoma 2Head & Neck 2Breast 2Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 4Adenoma, Islet Cell 2Tuberous Sclerosis 1Neoplasms 1Gastroenteropancreatic Neuroendocrine Tumors 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1

Interventions

Everolimus 2romidepsin 1regorafenib 1exemestane 1entrectinib 1cabozantinib 1alectinib 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Lactones 1LY2584702 1Injections 1Immunotherapy 1Erlotinib Hydrochloride 1Drug Therapy 1Depsipeptides 1Clinical Trials, Phase II as Topic 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Injections × NET × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡